Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers
HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers
HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss
HighField Biopharmaceuticals ASCO 2024 Poster Presentation Shows HFK1, a Unique Immunoliposome May Improve Clinical Outcomes over Antibody Drug Conjugates
HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R Agonist, for Treatment of Diabetes, at ADA’s 84th Scientific Sessions
BioSpace: Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers
Clinical Trials Arena: HighField Bio initiates its glioma trial with first patient dosing
Biospace: HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b/2 Trial of HF1K16 for Recurrent and Refractory Glioma
Biospace: HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers
ASCO Breakthrough 2024 Poster: Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma
American Diabetes Association 2024 Poster: Preliminary study of efficacy and duration of an mRNA based GLP-1R agonist in diabetic monkeys
Liposomes : Methods and Protocols: Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes)
mAbs : Liposomal T cell Engager and Re-director for Tumor Cell Eradication in Cancer Immunotherapy
Frontiers in Immunology : Sustained Drug Release from Liposomes for the Remodeling of Systemic Immune Homeostatis and the Tumor Microenvironment
Sustained Drug Release From Liposomes for the Remodeling of Systemic Immune Homeostasis and the Tumor Microenvironment
Comparative properties and methods of preparation of lipid vesicles (liposomes)
Gluagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy